Evidence map›Paper›PMID 36917358›Full record

ReviewPituitary2023

Refractory corticotroph adenomas.

Amit K S Sumal, Dongyun Zhang, Anthony P Heaney

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Pituitary, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Amit K S SumalDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Dongyun ZhangDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Anthony P HeaneyDepartment of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA. aheaney@mednet.ucla.edu.

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Development of 3-dimensional human pituitary corticotroph tumor cultures as a preclinical model for drug discoveryR01CA251930 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEANEY, ANTHONY P · 2021 to 2025
$1.8M
NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA251930
6 · The paper itself

Abstract

The majority of corticotroph adenomas are benign but some are locally invasive, demonstrate high rates of recurrence, and exhibit a relatively poor response to often repeated surgical, medical, and radiation treatment. Herein, we summarize the currently known somatic and genetic mutations and other molecular factors that influence the pathogenesis of these tumors and discuss currently available therapies. Although recent molecular studies have advanced our understanding of the pathogenesis and behavior of these refractory corticotroph adenomas, these insights do not reliably guide treatment choices at present. Development of additional diagnostic tools and novel tumor-directed therapies that offer efficacious treatment choices for patients with refractory corticotroph adenomas are needed.

Indexed as

ACTH-Secreting Pituitary AdenomaAdenomaPituitary NeoplasmsHumansRefractory corticotroph adenomas

Identifiers

PMID36917358
PMCPMC10333410

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.